TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 26:38 · AI Drug Discovery · Data-genomics convergence could raise human biology understanding from 15% to 50%, transforming healthcare economics
episode briefing
In Good Company with Nicolai Tangen

Kinnevik CEO Georgi Ganev and Chair James Anderson | Norges Bank Investment Management

2024-09-04 · 9 company · 6 thematic
sentiment
6 bull1 bear2 neu
speakers
georgi ganev

CEO of Kinnevik, a Swedish publicly listed investment company founded in 1936 with founding family ownership, focused on backing novel business models in healthcare, consumer, and technology with a multi-generational time horizon.

james anderson

Chair of Kinnevik and one of Europe's most successful technology investors, known for early backing of Tesla, Spotify, and other exponential companies; advocates scenario-based imagination over point forecasts and 10+ year holding periods.

now playing · AI Drug Discovery
Geopolitics & Tradeheadwindscore 7/10georgi ganev
European tech ecosystem suffers from ambition deficit versus US, not capability gap
Europe's startup disadvantage stems from lower ambition levels among both founders and investors—focused on regulatory boundaries rather than impossible outcomes—compounded by fragmented ma…
Public Markets & Valuationheadwindscore 8/10georgi ganev
Public markets systematically punish long-term R&D investment, creating advantage for patient private capital
Public market short-termism forces companies to optimize for quarterly results over decade-scale R&D (exemplified by Nvidia's 2006 near-death), giving private and permanent capital structur…
Venture Capitaltailwindscore 7/10georgi ganev
Private market structures enable long-term company building that public markets disrupt
Private company founders retain freedom to invest in multi-year innovation without daily share price pressure, while public listing introduces short-term evaluation metrics that conflict wi…
AI Infrastructuretailwindscore 8/10james anderson
AI compounding at 60% annually will transform healthcare, robotics, and autonomous driving within a decade
If AI continues compounding its power and understanding at ~60% per annum, the 10-year horizon enables solving previously intractable problems in healthcare (via data-genomics convergence),…
Clean Technologytailwindscore 7/10james anderson
Clean tech has superior scalable business models that markets underestimate
Clean technology sectors contain business models with better unit economics and scalability than conventional wisdom assumes, and these can be deployed at meaningful scale to drive returns.
AI Drug Discoverytailwindscore 8/10james anderson
Data-genomics convergence could raise human biology understanding from 15% to 50%, transforming healthcare economics
The intersection of AI-scale data and genomics offers a step-change in biological understanding that could shift drug discovery from low-probability pipeline bets to platform-driven enginee…